aminoglycosides Flashcards

1
Q

what are aminoglycosides?

A
Neomycin
Streptomycin
Spectinomycin
Gentamicin*
Tobramycin*
Amikacin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Entry into Bacterial Cell

amino considered bactericidal

A

 Cationic aminoglycosides (due to amino groups) bind to negatively charged anionic outer membrane protein,
lipopolysaccharides, polar heads of phospholipids in Gramnegative organisms
 Competitively displace cell wall Mg++ andCa++
 Causes rearrangement of lipopolysaccharide & formation of
transient holes
 Then enter cell through energy dependent processes
 EDP-1 (slow to cytosol), EDP-II (fast to ribosome, bacterial killing)
 entry into cell pH dependent (reduced at low pH or anaerobic
environment)
 Exhibit concentration-dependent killing effect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Mechanism of Action

A

Binds to 30S ribosomal binding sites in the mRNA decoding region of the 30S subunit

Interferes with mRNA binding sites & tRNA acceptor sites

“Infidelity in reading genetic code”

Production of “Fraudulent” Proteins

Elusive Effects
Lethal effects on bacterial cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Mechanisms of Acquired

Resistance

A

Enzymatic Modification ofAminoglycoside
 most common mechanism of resistance
 enzymes catalyse addition of acetyl, adenyl,
or phosphoryl grp inactivating aminoglycoside
 enzymes have overlapping affinities for
various aminoglycosides → may lead to cross-resistance
 enzyme production often plasmid mediated

Ribosomal Resistance
 Rare → loss of binding to streptomycin
Ineffective Transport Into Cell
 Rare (S. aureus)
Efflux
 MexXY efflux pump appears to explain
adaptive resistance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Adaptive Resistance

A

A transient resistance to aminoglycosides that follows the rapid, early, concentration-dependent killing of susceptible bacteria
 Lasts only a few hours but lasts beyond the post-antibiotic effect (PAE) into time of regrowth
 Due to the activation of the MexXY efflux pump that pumps out the aminoglycoside in the presence of aminoglycosides
 Resistance (and function of MexXY efflux pump) disappears as aminoglycoside concentrations approach 0
 Once daily dosing (Extended Interval Dosing (EID))
beneficial in reversing adaptive resistance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Spectrum of Activity

A

 facultative Gram-negative bacteria including Pseudomonas
 synergistic effects with cell wall activeagents
 synergistic with β-lactams and Vancomycinagainst:
 MSSAStaphylococci, MRSA
 Streptococci, (Viridans grp in endocarditis)
 Group B Streptococci
 Enterococcus faecalis (Gentamicin synergy 78% 2019)
Enterococcus faecium (Gentamicin synergy 87% 2019)
 Listeria

P. aeruginosa UAH 2019 All T 95%, G 90%
CF T 82%, G 63%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Added Spectrum

A

 Amikacin
 Mycobacteriumtuberculosis
 Mycobacterium avium

 Streptomycin
 Mycobacterium tuberculosis
 tularemia, Yersinia pestis

 Spectinomycin
 N. gonorrheae

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Absorption

A

very poorly absorbed orally
 Caution in renal failure – even small amounts absorbed may accumulate
 poor absorption topically unless severe skin damage
(e.g. major burns)
 very good absorption IM (equal to 20-30 min IV) unless
shock, edema etc.
 rapid absorption from peritoneum, pleura
 little absorption from bladder irrigations and intratracheal administration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Distribution

A

 Freely distributed to most interstitialspaces
 Distributes to extracellular fluid
 Crosses biological membranes poorly unless active transport system,
as in renal tubular cell where transport leads to toxicity
 Crosses poorly into CSF except in neonate
 eye
• distributes to cornea and aqueous
humour and slowly to vitreous humour
• subconjunctival and intravitreal
injections used in endopthalmitis
 Urinary concentration 25 -100 times serum levels and remains therapeutic for days
 Poor levels in prostate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Metabolism/Elimination

A

 > 90% eliminated unchanged renally

 t1/2 2-3 hours (normal renal function adults)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Toxicity

Three major toxicities

A
 Nephrotoxicity
 Ototoxicity
 Cochlear (hearing loss)
 Vesitibular (vertigo)
 Neuromuscular blockage(rare)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Nephrotoxicity

A

 5 - 25% of patients - usually mild and reversible
 Rarely - progression to dialysis-dependent renal failure
 ↑ SCr a good indicator (may be lag time inappearance)
 ↑ trough levels of aminoglycoside can be an early indicator with traditional dosing
 aminoglycosides transported across the renal tubular brush border cells through endocytosis and concentrated in proximal renal tubular cells (5-50x serum concentration), contributing to nephrotoxicity
 onset - usually after severaldays
 Accidental overdose of ≤ 1 day has not resulted in acute tubular necrosis
 Uptake of aminoglycosides by renal tubular cells, and possibly toxicity, is mediated by an endocytotic receptor megalin
 Through a complex mechanism the apoptotic pathway is activated, causing necrosis of cells in the renal proximal tubule

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Ototoxicity

 Damage may be cumulative with further doses of
aminoglycosides due to further damage to the hair cells
(cochlear or vestibular)
 May be potentiated by other ototoxic drugs such as cisplatin
or the loop diuretics (ethacrynic acid, furosemide)

A
 Recognized in 1940s withstreptomycin
 Aminoglycosides may cause
 Cochlear damage – hearing loss
 Vestibular damage – vertigo
 HearingLoss
 Damage to hair cells of organ of Corti in the cochlea
 Vestibulardysfunction
 Damage to hair cells of summit of ampullar cristae
in the vestibular complex

 may occur during therapy
 may occur weeks after therapy discontinued
 incidence of hearing loss has been reported to be as high as 62%
 overall incidence is quoted as 3 -14%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Cochlear Toxicity

A

 Drug accumulates in the endolymph and perilymph in the inner ear, resulting in damage to the sensory hair cells of the organ of Corti in the cochlea
 Limited regenerative capacity of sensory cells and
supporting cells
 Damage is oftenpermanent
 Future treatment with aminoglycosides may result
in additive cochlear toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Progression of Hearing Loss

A

Tinnitus and feeling of fullness in ears may be the first signs of ototoxicity
Tones of higher frequency lost first
 unnoticed by the patient
 Ideal to test by audiometry (pre and post administration)
Hearing loss progresses and lower frequency tones
(regular, speaking tones) affected
Hair cells do not usually regenerate, however some
damaged hair cells may develop improved function
Future doses of aminoglycosides may result in cumulative hearing loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Ototoxicity likely a function of

A
Ototoxicity likely a function of
 total exposure (AUC)
 concentrationsachieved
In the rat, the hair cell uptake
 rapid, dose dependent
 demonstrates early saturation
 increasing tissue t1/2 with
prolonged exposure
17
Q

Vestibular Toxicity - Vertigo

A

Drug accumulates in the endolymph and perilymph in the inner ear
resulting in damage to the hair cells of the summit of the ampullar
cristae in the vestibular complex
 manifested as imbalance, dizziness, and visual problems
 Imbalance is worse in the dark or if footing is uncertain
 Spinning vertigo is uncommon
 Visual symptoms, oscillopsia, results in transient
blurring of vision with head movements
 Age is a risk factor since normally vestibular ganglion cell
counts decrease with age so that by 80 years of age, only
about 50% of vestibular neurons remain

18
Q

long term vest toxicity

A

Initially dizziness, loss of balance, visual disturbances
Long-term
Patients may compensate with visual and proprioceptive
mechanisms
 May have problems with eyes closed, in thedark
 May have problems compensating in patients with
poor vision or proprioceptive difficulties
 hearing loss and vertigo usually consideredirreversible
 clinical reports & laboratory studies – may be some potential
for regeneration

19
Q

Toxicity – Risk Factors

A
Nephrotoxicity
 unadjusted dosages
 > 3 days treatment
 Pre-existing renal
failure/hepatic dysfunction
 Hypotension/volume depletion
 Frequent dosing interval
 Concomitant nephrotoxic
drugs (e.g. vancomycin,
amphotericin B, etc.)
 Previous aminoglycoside
Ototoxicity
 duration oftreatment
 dose
 hypovolemia(BUN/Cr)
 renal
failure/hepatic
dysfunction
 loopdiuretics
 Hypotension
 previousaminoglycoside
20
Q

Strategies to Reduce

Aminoglycoside Oto/Nephrotoxicity

A
 Limit use ofaminoglycosides
 Monitoring of serumlevels
 Avoiding other ototoxic/nephrotoxic drugs
 Automatic stoporders
 ? Once daily dosing ofaminoglyosides
21
Q

Neuromuscular Paralysis

A

 Rare
 Associated with high concentrations at
the neuromuscular junction
 Ensure dose given slowly over 20 - 30 minutes
 Enhanced by curare-like drugs,
succinylcholine, magnesium, and myasthenia gravis
 Can be treated with prompt administration of Ca
 (experimentally has inhibited myocardial and
vascular smooth muscle as well ?? clinical relevance)

22
Q

Gentamicin/Tobramycin

A

 treatment of serious Gram-negative infections
 Gentamicin > activity against Gram positives (including
Enterococci) and Serratia
(gentamycin synergistic with penicillins/ampicillin against
Enterococci)
 Tobramycin > activity against Pseudomonas
 May be cross-resistance
 Tobramycin ??? less nephrotoxic and ototoxic than
Gentamicin

23
Q

Amikacin

A

lower in vitro potency – must give higher doses
Potential Advantage
 May be stable to plasmid-mediatedenzymes

24
Q

Streptomycin

A

 primarily an antituberculardrug
• also treats tularensis, Yersina pestis, Brucella
 synergistic with penicillin or vancomycin
for S. viridans or Enterococcus
endocarditis (gentamicin usually preferred)
 often not used if patient > 50 yrs due to risk ofototoxicity
 least nephrotoxic, most ototoxic of aminoglycosides

25
Q

Spectinomycin

A

 only use - resistant N. gonorrheae

 not effective for pharyngeal gonorrhea

26
Q

Neomycin

A

 too toxic to be used systemically
 has been used topically (may cause skin sensitisation)
 e.g., Neosporin cream or ointment
 has been used as oral tablets 500 mg to sterilize GIT
(1g q4h x 2-3 days)
 hepatic encephalopathy
(250 mg tid-qid - 4 g/day orally)
 caution in renal failure (small amount absorbed
but not excreted in renal failure )

27
Q

Aminoglycoside Interactions

A

 AdditiveNephrotoxicity
 Amphotericin B, Cisplatin, Cyclosporin, ? Vancomycin
 AdditiveOtotoxicity
 Loop diuretics (e.g., furosemide, ethacrynic acid)
 ?Vancomycin
 Enhanced neuromuscular blockade with muscle
relaxants (e.g., succinylcholine)

 Penicillins (high dose) or in same IV bag may inactivate
aminoglycosides
 Give IV drugs separately (one hour apart)
 May also occur in vivo in severe renal failure
 May interfere with blood levels taken for PK
 (Oral Neomycin inhibits the oral absorption of penicillin
by as much as 50%)

28
Q

Plazomicin

A

 New aminoglycoside recently approved in USA
 Treatment of serious bacterial infections due to multidrugresistant Enterobacterales, including carbapenem-resistant
Enterobacterales